Lv4
590 积分 2024-02-21 加入
50236 GUIDE trial results after withdrawal in part 3: Long-term remission in patients with psoriasis treated with guselkumab within 15 months from onset of symptoms
10天前
已关闭
Effect of Biological Therapy for Psoriasis on the Development of Psoriatic Arthritis: A Population-Based Cohort Study
1个月前
已完结
Psoriatic arthritis risk in psoriasis patients receiving anti-IL-23 vs anti-IL-17: comparison of drug classes and individual agents
1个月前
已完结
Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of Psoriasis Area and Severity Index score
1个月前
已完结
587 Higher IL-10+ T cell and treg cell counts in psoriatic skin are associated with super-response to guselkumab: Data from the phase 3 guide trial
1个月前
已完结
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study
1个月前
已完结
Stapokibart Rapidly and Consistently Improves the Clinical Signs Across All Body Regions in Adults With Moderate‐to‐Severe Atopic Dermatitis
2个月前
已完结
63516 Higher Levels of Skin Clearance Across Body Regions with Upadacitinib versus Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
2个月前
已关闭
533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure
2个月前
已完结
Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trial
2个月前
已完结
皖公网安备34019202002308
